Novavax (MEX:NVAX) Construction In Progress: MXN0 Mil (As of Mar. 2026)


MEX:NVAX Novavax Inc MEX:NVAX
42 GF Score
Price MXN165.00
GF Value MXN65.56
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Novavax Construction In Progress?

Novavax MEX:NVAX -6.25% 42 Construction In Progress is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:NVAX with a GF Score™ of 42/100 and a GF Value™ of MXN65.56 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Novavax's quarterly construction in progress increased from Sep. 2025 (MXN0 Mil) to Dec. 2025 (MXN113 Mil) but then declined from Dec. 2025 (MXN113 Mil) to Mar. 2026 (MXN0 Mil).

Novavax's annual construction in progress declined from Dec. 2023 (MXN1,293 Mil) to Dec. 2024 (MXN824 Mil) and declined from Dec. 2024 (MXN824 Mil) to Dec. 2025 (MXN113 Mil).

Novavax Construction In Progress Historical Data

* Premium members only.

The historical data trend for Novavax's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Novavax Construction In Progress Chart

Novavax Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 720.33 1,590.21 1,292.69 824.07 112.93

Novavax Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 112.93 0.00
MEX:NVAX
42GF Score
Novavax Inc MEX:NVAX
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Novavax Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of MXN0 Mil mean?
Novavax (MEX:NVAX) has a Construction In Progress of MXN0 Mil as of Mar. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Novavax and its competitors.
Is Novavax's Construction In Progress too high?
Novavax's current Construction In Progress is MXN0 Mil. Overall, Novavax has a GF Score™ of 42/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Novavax's Construction In Progress compare to MPLT and COAG?
Novavax's Construction In Progress of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Novavax and its competitors. Novavax's current Construction In Progress is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novavax stock overvalued right now?
Based on GuruFocus' analysis, Novavax (MEX:NVAX) is currently considered Significantly Overvalued. The stock's GF Value™ is MXN65.56, compared to a current price of MXN165.00 — trading 151.7% above its estimated fair value. The current Construction In Progress is MXN0 Mil. Novavax's overall GF Score™ is 42/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Novavax (MEX:NVAX), the current Construction In Progress is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Novavax (MEX:NVAX) Overvalued in 2026?

Based on GuruFocus' analysis, Novavax stock appears to be overvalued. The current stock price of MXN165.00 is trading 151.7% above its estimated GF Value™ of MXN65.56. GuruFocus considers Novavax to be Significantly Overvalued.

Key valuation signals for MEX:NVAX:

  • Construction In Progress: MXN0 Mil
  • GF Value™: MXN65.56 vs. price of MXN165.00 (151.7% above fair value)
  • GF Score™: 42/100 with 7 warning signs

No single metric tells the full story. See the MEX:NVAX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Novavax Business Description

Address 21 Firstfield Road, Gaithersburg, MD, USA, 20878
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, an in-house early-stage R&D business to build a pipeline of high-value assets using its technology along with seeking to enter into partnerships to drive value creation for its assets.
42GF Score

Get the complete analysis for MEX:NVAX

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN165.00
Price
MXN65.56
GF Value